Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta‐analysis of non‐Asian studies
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16360 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Philip Home und 9 weiteren Autor:innen. Beteiligte Einrichtung: Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin Aspart, Insulin Glargine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To estimate the relative treatment effect of iGlarLixi (a fixed‐ratio combination of insulin glargine 100 U/mL plus lixisenatide) versus premixed insulin IDegAsp (insulin degludec plus insulin aspart) in people with type 2 diabetes (T2D) who advanced from basal insulin to iGlarLixi or IDegAsp in non‐Asian studies. Materials and Methods Randomized controlled trials (RCTs) were identified in a systematic review by searching Embase (including congress abstracts from 2021 to 2023), MEDLINE® and CENTRAL on 10 October 2023. Treatment outcomes from non‐Asian RCTs for people with T2D previously treated with basal insulin, who switched to iGlarLixi or IDegAsp, were compared using a network meta‐analysis (NMA). Data analysis was performed using R, version 4.0.2.
Results
The NMA included four RCTs ( N = 2535). The results of the NMA showed that iGlarLixi ( n = 810) was associated with a significantly greater reduction in HbA1c versus IDegAsp ( n = 454) (mean difference [MD]: −0.39 [95% credible interval, CrI: −0.58, −0.21] %‐units). iGlarLixi was also associated with a significantly greater likelihood of achieving an HbA1c of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
- Sanofi, Paris, France.
- Sanofi, Bridgewater, New Jersey, USA.
- Department of Internal Medicine, Diabetology Unit, Rashid Hospital, Dubai Health Authority, Dubai, United Arab Emirates.
- Departamento de Endocrinología y Metabolismo, UIEM, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, México City, Mexico.
- Faculty of Medicine of Oran, Université Oran 1, Oran, Algeria.
ORCID-Profile: Philip Home, Roopa Mehta
Förderung
- Sanofi
Zitieren
APA
Home, P., Lauand, F., Djaballah, K., Li, X. T., Hafidh, K., Mehta, R., Faraoun, K., Anaforoğlu, İ., Serafini, P., & Pourrahmat, M. M. (2025). Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta‐analysis of non‐Asian studies. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16360
Vancouver
Home P, Lauand F, Djaballah K, Li XT, Hafidh K, Mehta R, et al. Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta‐analysis of non‐Asian studies. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16360
BibTeX
@article{Home2025,
author = {Home, Philip and Lauand, Felipe and Djaballah, Khier and Li, Xuan-Tony and Hafidh, Khadija and Mehta, Roopa and Faraoun, Khadra and Anaforoğlu, İnan and Serafini, Paul and Pourrahmat, Mir-Masoud},
title = {Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta‐analysis of non‐Asian studies},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16360}
}
EUVIMED